NRAS and melanoma: Advances in access to next-generation sequencing platforms and wider uptake of screening for melanoma with traditionally nontargetable mutations such as NRAS may enable more efficient identification of patients with advanced melanoma who might benefit from novel targeted therapies alone or in combination with immunotherapy in future clinical studies.